API reference
Trilaciclib
- CAS number
- 1374743-00-6
- Molecular formula
- C24H30N8O
- Molecular weight
- 446.5 g/mol
About this molecule
Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage small cell lung cancer. CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy. Trilaciclib was first described in the literature in 2016. Trilaciclib was granted FDA approval on 12 February 2021.
Source: DrugBank, via PubChem.
Identifiers
- IUPAC name
- 4-[[5-(4-methylpiperazin-1-yl)-2-pyridinyl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one
- InChIKey
- PDGKHKMBHVFCMG-UHFFFAOYSA-N
- SMILES
- CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6
- PubChem CID
- 68029831
Also known as
Trilaciclib · G1T28 · trilaciclibum · G-1T28 · G1T28-1 · G1T28; Cosela · G1T28(Trilaciclib)? · Trilaciclib (G1T28)
Related entries in the range
Chemical data on this page is drawn from PubChem (National Library of Medicine) and is provided for identification only. Hanpars does not hold stock of every substance listed; availability, grade, documentation and regulatory status are confirmed per enquiry.
Tell us the grade, the quantity and the market.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.